Larimar Therapeutics (LRMR) Equity Average (2016 - 2020)
Historic Equity Average for Larimar Therapeutics (LRMR) over the last 7 years, with Q3 2020 value amounting to $107.6 million.
- Larimar Therapeutics' Equity Average rose 6299.55% to $107.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $107.6 million, marking a year-over-year increase of 6299.55%. This contributed to the annual value of $46.3 million for FY2019, which is 4601.55% down from last year.
- Per Larimar Therapeutics' latest filing, its Equity Average stood at $107.6 million for Q3 2020, which was up 6299.55% from $81.6 million recorded in Q2 2020.
- Larimar Therapeutics' 5-year Equity Average high stood at $161.8 million for Q1 2016, and its period low was $25.0 million during Q1 2020.
- Moreover, its 5-year median value for Equity Average was $87.8 million (2019), whereas its average is $92.3 million.
- Examining YoY changes over the last 5 years, Larimar Therapeutics' Equity Average showed a top increase of 6299.55% in 2020 and a maximum decrease of 7150.45% in 2020.
- Over the past 5 years, Larimar Therapeutics' Equity Average (Quarter) stood at $126.0 million in 2016, then crashed by 33.53% to $83.7 million in 2017, then grew by 17.77% to $98.6 million in 2018, then plummeted by 69.99% to $29.6 million in 2019, then soared by 263.57% to $107.6 million in 2020.
- Its last three reported values are $107.6 million in Q3 2020, $81.6 million for Q2 2020, and $25.0 million during Q1 2020.